Skip to content

Mark Elliott Boulding, Exec. VP and CLO at Ptc Therapeutics, sold PTCT on Jun 17, 2026

Data as of Oct 16

▼ SELL$518K6,600 shares at $78.50Mark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.
Watch PTCT
Traded
Jun 17, 2026
Disclosed
Jun 22, 2026
Filed
5 days after the trade · late

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Mark Elliott Boulding, Exec. VP and CLO at Ptc Therapeutics, sold PTCT on Jun 17, 2026TRADEDDISCLOSED
PTCTSimilar stocks (XLV — its sector index fund), rebased to PTCT's price on the disclosure day
PTCT since disclosure
−26.8%
after the sale
Similar stocks (XLV) since disclosure
+17.8%
XLV — its sector index fund

Change in closing price from Jun 22, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLMark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.$147Kdisclosed Jun 22 · filed 5 days after the trade · late
  2. ▼ SELLMark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.$24.5Kdisclosed Jun 22 · filed 5 days after the trade · late
  3. ▼ SELLMark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.$134Kdisclosed Jun 22 · filed 5 days after the trade · late

See every trade on PTCT →